Page last updated: 2024-08-25

3-deazaneplanocin and gefitinib

3-deazaneplanocin has been researched along with gefitinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, C; Chen, J; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Liu, M; Shi, R; Yuan, Y; Zhang, H; Zhang, Z	1

Other Studies

1 other study(ies) available for 3-deazaneplanocin and gefitinib

Article	Year
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. BMC cancer, 2020, Dec-04, Volume: 20, Issue:1 Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction	2020

Article

Year

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.

BMC cancer, 2020, Dec-04, Volume: 20, Issue:1

Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction

2020